Case Studies

Acutus Medical (NASDAQ: AFIB)

Acutus Medical, Inc’s (NASDAQ: AFIB) CEO David Roman recently spoke with Wall Street Analyzer to provide an overview of the company, discuss recent news, and go over key goals for the next 6-8 months. The company is focused on the treatment of atrial fibrillation and other cardiac arrhythmias and has a novel mapping system that enables physicians to visualize disease on a patient by patient basis and therefore has a higher success rate than current standard of care procedures. Mr. Roman went over AFIB’s recent Q3 results that included an over 50% increase in their international procedures and a 17% year to year growth in overall procedures. Perhaps the biggest announcement was the company’s deal with Medtronic for sale of their access portfolio, referred to as Left Heart Access (LHA), and consists of uncapped revenue based earn-outs for four years after the official launch. Acutus Medical produced $17.3 million in revenue in 2021. […]


Citius Pharmaceuticals (NASDAQ: CTXR)

Myron Holubiak, CEO of Citius Pharmaceuticals took time to update WSA’s listeners on the companies’ progress since their previous interview. Mr. Holubiak provided an overview of the progress on the CTXR’s main products Mino-Lok and Mino-Wrap and shared how they are adapting the product to deal with COVID compliance and restrictions. He also talked about other programs in early stage development and went over key factors that make Citius a unique investment opportunity. Have a look below: […]


Citius Pharmaceuticals (NASDAQ: CTXR) CEO Interview Update

Mino-Lok product has advanced to Phase 3 clinical studies. CITI-101 (Mino-Wrap) is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the high-potency steroid, halobetasol, with lidocaine. […]